用于治疗与更年期相关的中度至重度血管运动症状的费索利内坦 (SKYLIGHT 1): 一项3期随机对照研究
Samuel Lederman1, Faith D Ottery2, Antonio Cano3
1Altus Research, Lake Worth, FL, USA.
Lancet (London, England)
|March 16, 2023
概括
在更年期妇女中,Fezolinetant有效降低了中度至重度的血管运动症状. 这种非激素治疗显著改善了症状的频率和严重程度,为更年期治疗提供了新的选择.
科学领域:
- 药理学和治疗学
- 女性健康
- 内分泌学
背景情况:
- 血管运动症状 (VMS) 对更年期妇女的生活质量产生重大影响.
- 对于无法或不愿使用激素治疗的妇女,存在有限的非激素治疗选择.
- 神经素3受体抗剂代表了对VMS的新疗法.
研究的目的:
- 评估神经素3受体对抗剂fezolinetant在绝经后妇女中适度至重度VMS的安全性和有效性.
- 评估fezolinetant作为与更年期相关的发热症的非荷尔蒙疗法的潜力.
主要方法:
- SKYLIGHT 1试验是一个随机的,双盲的,安慰剂控制的,为期12周的3期试验,延长了40周.
- 参与者 (n=525) 每天接受安慰剂,30毫克或45毫克.
- 与4周和12周的基线相比,VMS频率和严重程度的变化是首要终点.
主要成果:
- 与安慰剂相比,费索利内坦 (30 mg 和 45 mg) 在第4周和第12周显著降低了VMS的频率和严重程度 (p< 0. 001).
- 症状在一周内得到改善,持续52周.
- 治疗引起的不良事件在各组之间是可比的;肝酶升高是罕见的和短暂的.
结论:
- 在治疗与更年期相关的中度至重度VMS时,Fezolinetant表现出显著的疗效和良好的安全性.
- 这些发现支持fezolinetant作为非激素治疗选择的临床使用.
- 进一步的研究应该探索fezolinetant对生活质量,情绪和性健康的影响.
相关概念视频
01:28Menopause
218
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
218
01:22Hormonal Regulation of the Menstrual Cycle
543
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
543
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
212
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
212
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
211
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
211
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
236
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
236
01:20Antiepileptic Drugs: Potassium Channel Activators
233
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
233